Cover Image
市場調查報告書

Microbiotix, Inc.:產品平台分析

Microbiotix, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 289817
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
Microbiotix, Inc.:產品平台分析 Microbiotix, Inc. - Product Pipeline Review - 2016
出版日期: 2016年03月30日 內容資訊: 英文 52 Pages
簡介

Microbiotix, Inc. 是正在開發治療C型肝炎及人類巨細胞病毒感染疾病之小分子治療藥的生物製藥公司。該公司同時也在進行對抗絲狀病毒、瘧疾、革蘭氏陰性菌感染疾病、結核病、流感的抗菌劑開發計劃。

Microbiotix, Inc.的基本資料

  • Microbiotix, Inc.概要
  • 主要資訊
  • 企業資料

Microbiotix, Inc.:R&D概要

  • 主要的治療範圍

Microbiotix, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Microbiotix, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Microbiotix, Inc.:藥物簡介

  • filociclovir
  • MBX-700
  • MBX-1162
  • MBX-500
  • MBX-701
  • MBX-900
  • Small Molecules to Inhibit 30S RNA for Tuberculosis
  • Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections
  • MBX-1090 Analogs
  • MBX-2168
  • MBX-2319
  • MBX-2329
  • MBX-2359
  • MBX-2402
  • MBX-2546
  • Small Molecule to Inhibit DNA Helicase for Infectious Diseases
  • Small Molecules for Ebola Virus Infection
  • Small Molecules for Gram-Negative Bacterial Infections
  • Small Molecules to Inhibit NPC1 for Filovirus Infections
  • Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax
  • Small Molecules to Inhibit bNOS for MRSA Infections
  • Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection
  • Small Molecules to Inhibit PSAC for Malaria
  • Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections

Microbiotix, Inc.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Microbiotix, Inc.:暫停中的計劃

Microbiotix, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08009CDB

Summary

Global Markets Direct's, 'Microbiotix, Inc. - Product Pipeline Review - 2016', provides an overview of the Microbiotix, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Microbiotix, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Microbiotix, Inc.
  • The report provides overview of Microbiotix, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Microbiotix, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Microbiotix, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Microbiotix, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Microbiotix, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Microbiotix, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Microbiotix, Inc. Snapshot
    • Microbiotix, Inc. Overview
    • Key Information
    • Key Facts
  • Microbiotix, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Microbiotix, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Microbiotix, Inc. - Pipeline Products Glance
    • Microbiotix, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Microbiotix, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Microbiotix, Inc. - Drug Profiles
    • filociclovir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-700
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-500
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-900
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 16S rRNA for Tuberculosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KKL-35
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2168
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2319
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2329
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2359
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2402
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2546
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit DNA Helicase for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Ebola Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Fungal Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Gram-Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit bNOS for MRSA Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit BoNT/A LC for Botulism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Synthesis for Gram-Negative and Gram-Positive Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit NPC1 for Filovirus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PSAC for Malaria
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit the Fatty Acid Synthesis II for Pseudomonas Aeruginosa Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Microbiotix, Inc. - Pipeline Analysis
  • Microbiotix, Inc. - Pipeline Products by Target
  • Microbiotix, Inc. - Pipeline Products by Route of Administration
  • Microbiotix, Inc. - Pipeline Products by Molecule Type
  • Microbiotix, Inc. - Pipeline Products by Mechanism of Action
  • Microbiotix, Inc. - Dormant Projects
  • Microbiotix, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Microbiotix, Inc., Key Information
  • Microbiotix, Inc., Key Facts
  • Microbiotix, Inc. - Pipeline by Indication, 2016
  • Microbiotix, Inc. - Pipeline by Stage of Development, 2016
  • Microbiotix, Inc. - Monotherapy Products in Pipeline, 2016
  • Microbiotix, Inc. - Phase I, 2016
  • Microbiotix, Inc. - Preclinical, 2016
  • Microbiotix, Inc. - Discovery, 2016
  • Microbiotix, Inc. - Pipeline by Target, 2016
  • Microbiotix, Inc. - Pipeline by Route of Administration, 2016
  • Microbiotix, Inc. - Pipeline by Molecule Type, 2016
  • Microbiotix, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Microbiotix, Inc. - Dormant Developmental Projects,2016

List of Figures

  • Microbiotix, Inc. - Pipeline by Top 10 Indication, 2016
  • Microbiotix, Inc. - Pipeline by Stage of Development, 2016
  • Microbiotix, Inc. - Monotherapy Products in Pipeline, 2016
  • Microbiotix, Inc. - Pipeline by Top 10 Target, 2016
  • Microbiotix, Inc. - Pipeline by Route of Administration, 2016
  • Microbiotix, Inc. - Pipeline by Molecule Type, 2016
  • Microbiotix, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top